Volpara Acquires Breast Cancer Risk Assessment Company CRA Health, LLC

Highlights:

• CRA Health, LLC (“CRA”), based in Boston, MA, is an industry leader in breast cancer risk assessment spun out from Massachusetts General Hospital, a Harvard Medical School teaching hospital

• CRA is profitable, 1 with Annual Recurring Revenue (ARR) of over US$4.0M (NZ$6.2M2 ), Average Revenue Per User (ARPU) of ~US$1.70 and coverage of ~6% of US breast screenings

• CRA’s software is integrated with the major Electronic Health Record (EHR) and genetics companies

• Volpara is paying US$18.0M for CRA, with a further US$4.0M payable upon meeting of key performance and staff-retention targets

• Post-acquisition, Volpara will have ARR of ~US$17.5M (NZ$26.9M2 ) and at least one product in use in over 30% of US breast screenings

• Post-acquisition, Volpara will have ~NZ$35M cash

• Volpara is elevated as a leader in personalised breast care